| This week's sponsor is Premier Research. | |  | Tips for Achieving the Most Success in Acute-Pain Drug Trials
Sponsors studying treatments for acute pain boost their odds of success when they optimize conduct of early trials. Read our white paper for helpful tips on study design, assessment, and operations. Premier Research. It's what we do. Best. |
Featured Story | | | Tuesday, September 12, 2017 New FDA Commissioner Scott Gottlieb wants to target drug development costs as yet another study asks how much it really costs to make a medicine. |
|
|
| This week's sponsor is Fierce Innovation Awards. | |  | Now Accepting Applications! Deadline: Friday, October 20th
Does your product/service have the potential to transform the biotech or pharma industry? This is your chance to submit an application and have your solution reviewed by our expert panel of judges. Apply today! |
Top Stories Tuesday, September 12, 2017 Onxeo’s Livatag has failed to beat the active control in a phase 3 hepatocellular carcinoma (HCC) trial. The setback wiped about 50% off Onxeo’s share price as investors adjusted to the diminished expectations for the doxorubicin-loaded nanoparticle candidate. Tuesday, September 12, 2017 Alexion is slashing its workforce by around 20% and closing sites in a bid to save $250 million a year, with R&D bearing the brunt and accounting for around two-thirds of the cost cutting. Monday, September 11, 2017 When it comes to healthcare we know that consumers actively participate in social media to seek information and find support. More than 40% say that information from social media affects how they cope with a chronic condition, their approach to diet and exercise, the physician they select and even their decision to seek a second opinion1. Tuesday, September 12, 2017 Erytech is preparing to move eryaspase into a pivotal trial after full data from a phase 2b affirmed earlier top-line results. The red-blood-cell-encapsulated L-asparaginase improved overall survival and other outcomes in metastatic pancreatic cancer patients, emboldening Erytech to consider swinging for first-line use in phase 3. Tuesday, September 12, 2017 After M&A hype and a small win for a midstage major depressive disorder test earlier this year, Sage Therapeutics has seen its shares soar. But today it was brought down to earth with a late-stage failure for brexanolone. Tuesday, September 12, 2017 Though immuno-oncology treatments have transformed the standard of care, many patients don’t respond to PD-1 therapies, and those who do can develop resistance. Hoping to combat that, Bristol-Myers is moving a new LAG-3 drug, relatlimab, into late-stage testing. Tuesday, September 12, 2017 Tiny Aldeyra Therapeutics says it has seen “statistically and clinically significant improvements” in a midstage trial for its experimental eye med ADX-102, although not all data points were positive. Tuesday, September 12, 2017 Following a sales fraud investigation that led to major executive changes, Alexion’s new management is rolling out its first corporate overhaul. The rare disease biotech on Tuesday announced a restructuring that includes cutting 20% of its staff and moving its headquarters to the Boston biopharma hub. Resources Sponsored by: Ashfield Healthcare Join this webinar to learn how to design, deliver, and measure a successful patient support program. Presented by Nareda Mills, Ashfield's SVP of Patient Services in the US, you’ll discover how to improve adherence and improve patient outcomes using 5 key methods. Presented By: PRA Health Sciences Children participating in pediatric clinical trials are included in the contraceptive requirements applied to women of child-bearing potential, creating significant challenges for sponsors, parents, investigators and study staff. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. | 
